id: sud_medication_treatment_rate_oud_to_NEW:time_to_first_arrest
name: OUD Medication Treatment Rate (Extended Release Naltrexone) â†’ Time to First Arrest
from_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: OUD Medication Treatment Rate (Extended Release Naltrexone)
to_node:
  node_id: NEW:time_to_first_arrest
  node_name: Time to First Arrest
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: XR-NTX administered to criminal justice-involved individuals with OUD upon release'
- 'Step 2: Medication blocks opioid effects but does not provide comprehensive reentry support'
- 'Step 3: Structural barriers (housing instability, unemployment, lack of social support) remain unaddressed'
- 'Step 4: No significant difference in time to first arrest between treatment groups'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: William E Soares et al. 2019. "Incidence of future arrests in adults involved in the
    criminal justice system with opioid use disorder receiving extended release naltrexone compared to
    treatment as usual.." https://doi.org/10.1016/j.drugalcdep.2018.10.035
  supporting_citations:
  - Additional citations require full-text access
  doi: 10.1016/j.drugalcdep.2018.10.035
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Time to first arrest did not significantly differ between XR-NTX and TAU groups (adjusted
  HR 1.35, CI 0.96-1.89), indicating that medication treatment for OUD does not delay recidivism without
  addressing broader structural determinants of criminal justice involvement.
quantitative_effects:
  effect_size:
    value: 1.35
    type: hazard_ratio
    ci_lower: 0.96
    ci_upper: 1.89
  sample_size: 300
structural_competency:
  equity_implications: The lack of effect on time to arrest further supports the conclusion that addressing
    opioid use alone through pharmacotherapy is insufficient. Criminal justice involvement is driven by
    multiple structural factors including poverty, lack of opportunity, and systemic marginalization that
    persist regardless of medication status.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.579392'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
